Mark H Gotfried
Overview
Explore the profile of Mark H Gotfried including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
710
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodvold K, Gotfried M, Ussery X, Wong S, Hamed K
Antimicrob Agents Chemother
. 2024 Oct;
68(11):e0110324.
PMID: 39352135
SPR720 is a phosphate ester prodrug that is converted rapidly to SPR719, the active moiety, which exhibits potent activity against clinically relevant mycobacterial species including complex (MAC) and . SPR720...
2.
Gotfried M, Auerbach S, Dang-Vu T, Mishima K, Kumar D, Moline M, et al.
Drugs Aging
. 2024 Aug;
41(9):741-752.
PMID: 39120786
Background: Insomnia is more common as people age. Several common hypnotics used to treat insomnia often do not adequately alleviate sleep issues in older adults and may be associated with...
3.
Rodvold K, Gotfried M, Gupta V, Ek A, Srivastava P, Talley A, et al.
Antimicrob Agents Chemother
. 2022 Jun;
66(7):e0059022.
PMID: 35762796
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral carbapenem prodrug being developed for the treatment of serious bacterial infections. The active moiety, tebipenem, has broad-spectrum activity against common pathogens, including extended-spectrum-β-lactamase...
4.
Gotfried M, Girod C, Antin-Ozerkis D, Burgess T, Strombom I, Stauffer J, et al.
Pulm Ther
. 2020 Feb;
4(1):59-71.
PMID: 32026243
Introduction: PIPF-002 was a phase 2, multicenter, open-label study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) or other types of pulmonary fibrosis (PF). PIPF-002 terminated after pirfenidone became...
5.
Rodvold K, Gotfried M, Isaacs R, ODonnell J, Stone E
Antimicrob Agents Chemother
. 2018 Aug;
62(11).
PMID: 30126953
ETX2514 is a novel β-lactamase inhibitor that broadly inhibits Ambler class A, C, and D β-lactamases. ETX2514 combined with sulbactam (SUL) restores sulbactam activity against ETX2514-sulbactam (ETX2514SUL) is under development...
6.
Rodvold K, Gotfried M, Chugh R, Gupta M, Patel A, Chavan R, et al.
Antimicrob Agents Chemother
. 2018 May;
62(8).
PMID: 29784852
WCK 5222 is a combination of cefepime and the novel β-lactam enhancer zidebactam being developed for the treatment of serious Gram-negative bacterial infections. The objective of this study was to...
7.
Rizk M, Rhee E, Jumes P, Gotfried M, Zhao T, Mangin E, et al.
Antimicrob Agents Chemother
. 2018 Jan;
62(3).
PMID: 29311084
This phase I study assessed the intrapulmonary pharmacokinetic profiles of relebactam (MK-7655), a novel β-lactamase inhibitor, and imipenem. Sixteen healthy subjects received 250 mg relebactam with 500 mg imipenem-cilastatin, given...
8.
Rodvold K, Gotfried M, Chugh R, Gupta M, Yeole R, Patel A, et al.
Antimicrob Agents Chemother
. 2017 Dec;
62(3).
PMID: 29263070
Alalevonadifloxacin (WCK 2349) is a novel l-alanine ester prodrug of levonadifloxacin that is being developed as an oral fluoroquinolone antibiotic. The primary objective of this study was to determine and...
9.
Gotfried M, Horn K, Garrity-Ryan L, Villano S, Tzanis E, Chitra S, et al.
Antimicrob Agents Chemother
. 2017 Jul;
61(9).
PMID: 28696233
The steady-state concentrations of omadacycline and tigecycline in the plasma, epithelial lining fluid (ELF), and alveolar cells (AC) of 58 healthy adult subjects were obtained. Subjects were administered either omadacycline...
10.
Rodvold K, Gotfried M, Chugh R, Gupta M, Friedland H, Bhatia A
Antimicrob Agents Chemother
. 2017 Jul;
61(9).
PMID: 28696231
The nafithromycin concentrations in the plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM) of 37 healthy adult subjects were measured following repeated dosing of oral nafithromycin at 800 mg...